These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Statistical Profiling of One Promiscuous Protein Binding Site: Illustrated by Urokinase Catalytic Domain. Cerisier N; Regad L; Triki D; Petitjean M; Flatters D; Camproux AC Mol Inform; 2017 Oct; 36(10):. PubMed ID: 28696518 [TBL] [Abstract][Full Text] [Related]
3. Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Liang J; Edelsbrunner H; Woodward C Protein Sci; 1998 Sep; 7(9):1884-97. PubMed ID: 9761470 [TBL] [Abstract][Full Text] [Related]
4. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor. Nagase K; Kobayashi H; Yoshikawa E; Kurita N J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319 [TBL] [Abstract][Full Text] [Related]
5. Structure of human urokinase plasminogen activator in complex with its receptor. Huai Q; Mazar AP; Kuo A; Parry GC; Shaw DE; Callahan J; Li Y; Yuan C; Bian C; Chen L; Furie B; Furie BC; Cines DB; Huang M Science; 2006 Feb; 311(5761):656-9. PubMed ID: 16456079 [TBL] [Abstract][Full Text] [Related]
6. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations. Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990 [TBL] [Abstract][Full Text] [Related]
7. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Jankun J; Skrzypczak-Jankun E Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907 [TBL] [Abstract][Full Text] [Related]
8. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop. Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921 [TBL] [Abstract][Full Text] [Related]
9. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Ploug M Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416 [TBL] [Abstract][Full Text] [Related]
11. Protein pockets: inventory, shape, and comparison. Coleman RG; Sharp KA J Chem Inf Model; 2010 Apr; 50(4):589-603. PubMed ID: 20205445 [TBL] [Abstract][Full Text] [Related]
12. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis. Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782 [TBL] [Abstract][Full Text] [Related]
13. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation. Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907 [TBL] [Abstract][Full Text] [Related]
14. Shape variation in protein binding pockets and their ligands. Kahraman A; Morris RJ; Laskowski RA; Thornton JM J Mol Biol; 2007 Apr; 368(1):283-301. PubMed ID: 17337005 [TBL] [Abstract][Full Text] [Related]
15. Visualisation of variable binding pockets on protein surfaces by probabilistic analysis of related structure sets. Ashford P; Moss DS; Alex A; Yeap SK; Povia A; Nobeli I; Williams MA BMC Bioinformatics; 2012 Mar; 13():39. PubMed ID: 22417279 [TBL] [Abstract][Full Text] [Related]
16. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680 [TBL] [Abstract][Full Text] [Related]
17. Geometry of GPPE binding to picrate and to the urokinase type plasminogen activator. Zesławska E; Stürzebecher J; Oleksyn BJ Bioorg Med Chem Lett; 2007 Nov; 17(22):6212-5. PubMed ID: 17905583 [TBL] [Abstract][Full Text] [Related]
18. Detection of pockets on protein surfaces using small and large probe spheres to find putative ligand binding sites. Kawabata T; Go N Proteins; 2007 Aug; 68(2):516-29. PubMed ID: 17444522 [TBL] [Abstract][Full Text] [Related]
19. Boosting the sensitivity of ligand-protein screening by NMR of long-lived states. Salvi N; Buratto R; Bornet A; Ulzega S; Rentero Rebollo I; Angelini A; Heinis C; Bodenhausen G J Am Chem Soc; 2012 Jul; 134(27):11076-9. PubMed ID: 22686687 [TBL] [Abstract][Full Text] [Related]
20. Form follows function: shape analysis of protein cavities for receptor-based drug design. Weisel M; Proschak E; Kriegl JM; Schneider G Proteomics; 2009 Jan; 9(2):451-9. PubMed ID: 19142949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]